Skip to main
PYPD

PolyPid (PYPD) Stock Forecast & Price Target

PolyPid (PYPD) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

PolyPid is a clinical-stage biopharmaceutical company with a proprietary drug delivery technology platform that has the potential to target a wide variety of drugs for localized and extended-release delivery. With a market capitalization of ~$74M and an attractive risk-reward profile, the company has successfully executed on regulatory, partnering, and corporate fronts. Management's focus on both short-term and longer-term opportunities, along with a robust pipeline of candidates, has the potential to drive incremental intellectual property and generate future partnering or internal development opportunities. The company's execution across clinical, regulatory, and commercial pathways supports a positive outlook and potential unlocking of value with approval of their lead product candidate D-PLEX100. While there may be financing risks and a key bottleneck during the approval process is a successful FDA inspection, potential grants and designations, along with a pragmatic go-to-market strategy, provide optimism for a favorable outcome.

Bears say

PolyPid is facing potential risks in the short and medium term, including potential clinical and regulatory setbacks and delays in securing funding. These risks could impede market penetration of their product and lead to potential revenue erosion. The company's current financials and forecasted DCF analysis result in a price target of $9 per share, with potential for revenue contributions in 2036.

PolyPid (PYPD) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PolyPid and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PolyPid (PYPD) Forecast

Analysts have given PolyPid (PYPD) a Strong Buy based on their latest research and market trends.

According to 4 analysts, PolyPid (PYPD) has a Strong Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PolyPid (PYPD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.